{"id":13670,"date":"2011-03-15T10:00:00","date_gmt":"2011-03-15T09:00:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/usa-astrazeneca-paghera-685-mln-per-marketing-scorretto-di-seroquel\/"},"modified":"2011-03-15T10:00:00","modified_gmt":"2011-03-15T09:00:00","slug":"usa-astrazeneca-paghera-685-mln-per-marketing-scorretto-di-seroquel","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/usa-astrazeneca-paghera-685-mln-per-marketing-scorretto-di-seroquel\/","title":{"rendered":"Use: AstraZeneca will pay 68.5 million for incorrect marketing of Seroquel"},"content":{"rendered":"<p><span style=\"font-family: &quot;Verdana&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\"><font size=\"3\">AstraZeneca to pay an additional $68.5 million to settle US lawsuits over malpractice practices <em><span style=\"font-family: &quot;Verdana&quot;,&quot;sans-serif&quot;\">marketing&nbsp; <\/span><\/em>for the antipsychotic Seroquel (quetiapine). The allegations relate to alleged activities aimed at promoting the use of the drug not approved by the regulatory authorities and inadequate information on possible side effects. The settlement, with 37 states and the District of Columbia, is separate from the one signed in 2010 that resulted in a $520 million payment from the company to the US government to settle similar litigation.<\/font><\/span><\/p>\n<p><span style=\"font-family: &quot;Verdana&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\"><\/p>\n<p><span style=\"font-family: &quot;Verdana&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: IT; mso-ansi-language: IT; mso-bidi-language: AR-SA\"><em>(The Wall Street Journal online \u2013 10\/03\/2011 , International Herald Tribune Pag.19 \u2013 11\/03\/2011) <img","protected":false},"excerpt":{"rendered":"<p>AstraZeneca pagher&agrave; ulteriori 68,5 mln di dollari per porre fine a cause legali in Usa per procedure&nbsp;scorrette di marketing&nbsp; per l&#8217;antipsicotico Seroquel (quetiapina). Le accuse riguarderebbero presunte attivit&agrave; mirate a promuovere utilizzi del farmaco non approvati dalle autorit&agrave; regolatorie e la non adeguata informazione su possibili effetti secondari. L&#8217;accordo, con 37 Stati e il Distretto &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13670"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13670\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}